Hospital readmissions in the first weeks following surgery are common, expensive, and associated with increased mortality among colorectal cancer patients. This study is designed to assess the 30-day hospital readmission after colorectal cancer surgery and evaluate the risk factors that affect hospital readmission.
Methods
The study uses data from the Ministry of National Guard-Health Affairs Cancer Registry. All colorectal cancer patients who underwent colorectal cancer surgery between January 1, 2016, and November 31, 2021, were investigated. Factors examined were age, gender, marital status, Body Mass Index, Charlson Comorbidity Index, chemotherapy, radiotherapy, tumor stage, grade, site, surgical approach, length of stay, and discharge location. Kaplan–Meier curves were constructed to assess survival rates between readmitted and non-readmitted patients, and logistic regressions were performed to assess predictors of readmission.
Results
A total of 356 patients underwent tumor resection and 49 patients were readmitted within 30-day of index discharge. The most common reasons for hospital readmissions were gastrointestinal (22.45%), urinary tract infection (16.33%), and surgical site infection (12.24%). In the multivariable analysis, females were 89% more likely to be readmitted compared to males (odds ratio 1.89, 95% confidence intervals 1.00–3.58). Patients with distant metastatic tumors have higher odds of readmission (odds ratio 4.52, 95% confidence intervals 1.39–14.71) compared to patients with localized disease.
Conclusions
Colorectal cancer readmission is more common in patients with metastatic disease. Strategies to reduce readmission include planned transition to outpatient care, especially among patients with a high risk of readmission.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
CRC
Colorectal cancer
MNG-HA
Ministry of National Guard-Health Affairs
ICD
International classification of diseases
OS
Overall survival
SSI
Surgical site infections
CCI
Charlson comorbidity index
BMI
Body mass index
Introduction
Colorectal cancer (CRC) is the most diagnosed cancer in Saudi males and the third most common cancer in females, with a 5-year observed survival rate of 52% [1,2]. Given the improved outcomes associated with the surgical resection of CRC, surgery remains the principal treatment modality for patients diagnosed with CRC [3]. Nonetheless, surgical outcomes including hospital readmission during the first weeks after surgery are prevalent, costly, and implicated with increased mortality [4‐6]. Patients with cancer who have been discharged from hospitals have a readmission rate of up to 27% [7] and constitute a healthcare burden associated with morbidity and mortality [4]. No prior studies assessed the CRC rate of hospital readmissions and the risk factors associated with readmission among the Saudi population.
International studies, however, have evaluated CRC surgical outcomes including the 30-day hospital readmission and its predictors. Several reasons were associated with readmission including age, gender, race/ethnicity, type of health insurance, socioeconomic status (SES), tumor stage, comorbidities, procedure type, surgical approach (open or laparoscopic), length of hospital stay (LOS), surgical complications, non-home discharge, blood transfusion, and stoma creation [8]. Whether the rate and predictors of CRC readmissions are the same in the Saudi population remains unknown. This is vital given the poor characteristics of CRC in the Saudi population such as late-stage at diagnosis and low survival [9].
Anzeige
In Saudi Arabia, the total number of surgeries during the year 2020 was 398,188 and 46,831 of them were implemented at the Ministry of National Guard- Health Affairs (MNG-HA) [10]. More than 80% of the CRC patients at the MNG-HA are treated surgically [11], and hence elucidating the surgical outcomes of these patients is crucial. Similar to the US Veteran Affairs (VA) health system, the MNG-HA is a health system that covers eligible members in all regions of Saudi Arabia. Moreover, at the national level, Saudi Arabia has developed 12 strategic programs including a health sector transformation program that is mainly focusing on improving the population's health through efficient use of resources.
The present study aims to assess the 30-day hospital readmission after index colorectal cancer surgery and evaluates the risk factors that impact hospital readmission. We principally focused on the impact of demographic variables, tumor characteristics including the stage at diagnosis and LOS. We also investigated the reasons for hospital readmission. Identifying the rate of readmission and its predictors will contribute to the development of interventions that should reduce readmission, hospitalization costs and improve cancer patient outcomes.
Materials and methods
Data sources
The current study is a retrospective cohort study that uses data from the MNG-HA Cancer Registry linked with BESTCare, a medical record database within the MNG-HA system. The cancer registry contains information on patients’ demographics, clinical variables including tumor primary site, the stage at the time of diagnosis, and tumor grade for all patients who were diagnosed and treated at MNG-HA in Riyadh, Saudi Arabia. This study was approved by King Abdullah International Medical Research Center (NRC21R/432/10).
Study population
All patients with histopathologically confirmed CRC diagnosis between January 1, 2016, and November 30, 2021, and ≥ 18 years old at the time of diagnosis among the MNG-HA population were included in the study. The MNG-HA population consists of military service members and their dependents, the civilian workforce, and healthcare students from the MNG-HA healthcare system. The population of more than one million individuals is served by tertiary care hospitals and four main primary and secondary care clinics.
Anzeige
Study variables
Patient and tumor characteristics
Patient demographics were retrieved from the BESTCare system, including age at diagnosis, gender, marital status, and body mass index (BMI). Additional clinical variables such as comorbidities, chemotherapy, and radiotherapy were all retrieved. Inpatient records were used to gather surgical information such as type of surgery, LOS, surgery approach, operation duration, discharge location, admission, and discharge information.
Detailed tumor characteristics that were retrieved from the cancer registry include tumor site, topography, morphology, grade, and stage. The anatomic tumor location was categorized according to the International Classification of Diseases (ICD) for Oncology-third edition topography as follows: right colon (i.e., cecum, ascending colon, hepatic flexure of the colon, and transverse colon), left colon (i.e., splenic flexure of the colon, descending colon, and sigmoid), rectum (rectosigmoid junction and rectum) and colon not otherwise specified (NOS).
Outcome variables
CRC surgery was defined as the resection of the primary tumor with or without stoma creation within 1 month before or 12 months after CRC diagnosis. The 30-day readmission was defined as a hospitalization that occurred within 30 days of index discharge. Readmissions were identified using the inpatient records through admission and discharge dates. We also assessed overall survival in the study population. Follow-up time started from the index discharge date until the date of death, date of the last contact, or when the follow-up ended on January 31, 2022.
Statistical analysis
Categorical variables were assessed using the chi-square test and Fisher exact test. The student t-test was used for comparing means, while Wilcoxon tests for comparing medians. Penalized logistic regression models with Firth correction were used to estimate the univariate and multivariable associations between readmission and covariates [1,2]. Forward elimination was used during the multivariable analysis with a criterion for entering variable to the model at P ≤ 0.15. These variables were gender, marital status, stage at diagnosis, and discharge location. We compared the death rate between readmitted and non-readmitted patients and generated the survival curves using the Kaplan–Meier method. The differences in survival estimates were compared using the log-rank test. All statistical tests were 2-sided, and findings were considered statistically significant at P ≤ 0.05. Data were analyzed using SAS statistical software version 9.4 (SAS Institute Inc. Cary, NC).
Results
Figure 1 shows the eligibility criteria for the study population. In the present study, 356 patients were included, and 49 (13.76%) of them were readmitted, while the remaining were non-readmitted patients (Table 1). The average age was 60.79 years with almost 60% of the sample being males and more than 78% were married. The average BMI was 27.28 kg/m2 and nearly 70% of the patients did not have any comorbid conditions. Compared to the readmitted patients, non-readmitted individuals were more likely to be male and presented with regional stage at diagnosis. There was a significant association between stage at diagnosis and hospital readmission (P value = 0.03).
Table 2 displays the characteristics of the index surgery stratified by readmission status. The majority of the patients have a tumor located in the colon (83.71%) and the rest were in the rectum. Whereas 69.70% of the patients underwent open surgery, only 30.40% underwent laparoscopic surgery. Most patients had elective surgery (84.55%) and were discharged to the post-anesthesia care unit (82.87%). Furthermore, reasons for hospitalization after index discharge are reported in Table 3 and Additional file 1: Appendix 1. The recorded reasons were gastrointestinal (18.42% colon vs. 36.36% rectum), urinary tract infection (21.05% colon vs. 0% rectum), surgical site infection (13.16% colon vs. 9.09% rectum) and stoma related (2.63% colon vs. 27.27% rectum). Almost a quarter of readmission were due to gastrointestinal causes such as anastomotic leak, bowel obstruction, perforated tumor and rectal bleeding/discharge. Nevertheless, none of the differences were significant.
Table 2
Index surgery characteristics by 30-days readmission status, NGHA 2016–2021 (N = 356)
Readmitted
Non-readmitted
Total
P
N
% or SD
N
% or SD
N, % or SD
Tumor location
Colon
38
77.55
260
54.69
298 (83.71)
0.20
Rectum
11
22.45
47
15.31
58 (16.29)
Surgery approach
Laparoscopic
13
26.53
95
30.94
108 (30.43)
0.53
Open
36
73.47
212
69.06
248 (69.66)
Surgery type
Elective
43
87.76
258
84.04
301 (84.55)
0.84
Emergency
5
10.20
34
11.07
39 (10.96)
Other
1
2.04
15
4.89
16 (4.49)
LOS (median, IQR)
10.0
9.0
9.0
8.0
9.0 (8.0)
0.61
Discharge location
Central Post Anesthesia Care Unit
38
77.55
257
83.71
295 (82.87)
0.05
Intensive Care Unit
6
12.24
41
13.36
47 (13.20)
Other
5
10.20
9
2.93
14 (3.93)
Operation time (minutes)
205.90
131.65
234.11
101.75
230.22 (106.60)
0.15
Table 3
Reasons for 30-day hospital readmission after surgery (n = 49)
Reasons for readmission
Rectum N (%)
N = 11
Colon N (%)
N = 38
Total N (%)
N = 49
P
Gastrointestinal
4 (36.36)
7 (18.42)
11 (22.45)
0.20
Urinary tract infection
0 (0)
8 (21.05)
8 (16.33)
0.21
Surgical site infection
1 (9.09)
5 (13.16)
6 (12.24)
0.71
Stoma related
3 (27.27)
1 (2.63)
4 (8.16)
0.08
Cardiovascular
0 (0)
2 (5.26)
2 (4.08)
1.0
Others
3 (27.27)
15 (39.47)
18 (36.73)
0.45
In the univariate analysis, there was a positive association between age and readmission and females had higher odds of readmission than males, but both did not reach a significance level (Table 4). On the contrary, compared to patients diagnosed with a localized tumor, those diagnosed with distant metastatic disease have 4.09 higher odds of readmission (odds ratio 4.09, 95% confidence intervals 1.29–12.98). Likewise, patients discharged to locations other than post-anesthesia care or ICU have 3.75 higher odds of readmission (odds ratio 3.75, 95% confidence intervals 1.19–11.80).
Table 4
Univariate and multivariable analysis of risk factors for 30-day readmission, NGHA 2016–2021
Univariate analysis
Multivariate analysis
OR
95% CI
OR
95% CI
Age
≤ 40
1.0
1.0
41–50
1.08
(0.24, 4.90)
51–60
1.84
(0.49, 6.84)
61–70
1.65
(0.44, 6.18)
≥ 71
1.38
(0.36, 5.26)
Gender
Male
1.0
1.0
Female
1.67
(0.91,3.05)
Marital status
Single
1.0
1.0
Married
2.92
(0.38, 22.56)
Divorces/widowed
0.80
(0.05, 13.81)
Unknown
1.82
(0.19, 17.69)
Body mass index (BMI)
Under weight
2.22
(0.63, 7.86)
Healthy weight
1.0
1.0
Overweight
0.55
(0.25, 1.19)
Obese
0.71
(0.33, 1.51)
CCI
0
1.0
1.0
1
0.69
(0.31, 1.57)
> 1
0.97
(0.35, 2.67)
Stage at diagnosis
Localized
1.0
1.0
1.0
1.0
Regional
1.76
(0.59, 5.27)
1.59
(0.55, 4.58)
Distant metastasis
4.09
(1.29, 12.98)
3.86
(1.26,11.85)
Missing
1.59
(0.16, 16.13)
2.19
(0.27,17.45)
Pathological grading
Well differentiated
1.0
1.0
Moderately diferentiated
0.89
(0.10, 7.65)
Poorly differentiated
1.88
(0.18, 19.53)
Unknown
1.09
(0.08, 14.66)
Tumor morphology
Adenocarcinoma (AC), NOS
1.0
1.0
Mucinous AC
2.16
(0.42, 11.06)
Others
1.17
(0.39, 3.59)
Tumor site
Right colon
1.0
1.0
Left colon
1.41
(0.54, 3.72)
Colon-nonspecified
1.29
(0.46, 3.65)
Rectum
2.06
(0.71, 6.02)
Chemotherapy
Yes
1.0
1.0
No
0.67
(0.28, 1.62)
Radiotherapy
Yes
1.0
1.0
No
0.65
(0.35, 1.22)
Surgery approach
Laparoscopic
1.0
1.0
Open
1.24
(0.63, 2.45)
Surgery type
Elective
1.0
1.0
Emergency
0.88
(0.33, 2.38)
Other
0.4
(0.05, 3.10)
LOS
≤ 9 Days
1.0
1.0
> 9 Days
1.29
(0.71, 2.37)
Discharge location
Central Post Anesthesia Care Unit
1.0
1.0
1.0
1.0
Intensive Care Unit
0.98
(0.39, 2.49)
1.0
(0.40, 2.48)
Other
3.75
(1.19, 11.80)
4.19
(1.31, 13.42)
Bold values indicate significant results at p-value = 0.05
In the multivariable analysis, both patients diagnosed with distant metastatic tumors and those discharged to locations other than post-anesthesia care or ICU have higher odds of readmission (Table 4). Finally, for the mortality outcome, there is no statistically significant difference in the survivability amongst those readmitted and those not readmitted (P = 0.0581) (Fig. 2).
×
Discussion
In this retrospective population-based cohort study, we found that 13.76% of CRC patients were readmitted within 30-day of index hospitalization, a finding that is slightly higher than previous studies (9–11%) [4,12‐17]. The majority of recorded reasons for hospital readmissions were gastrointestinal (22.45%), urinary tract infection (16.33%), and surgical site infection (12.24%). Almost one-quarter of metastatic patients were readmitted within 30 day of index hospitalization.
While previous studies found that 22% to 27% of metastatic CRC patients were readmitted [18‐21,24], we observed that 24.30% (17/70) of our metastatic patients were readmitted. In the multivariable analysis, metastatic patients had 3.86 higher odds of 30-day hospital readmission compared to those with localized disease, similar to previous findings [22,23]. Several studies from Saudi Arabia have shown that a sizable percentage of Saudi CRC patients were diagnosed at an advanced stage [2,9], a risk factor that has been shown to increase readmission in our population. Moreover, we found that patients discharged to locations other than post anesthesia care unit were more likely to be readmitted.
Taken together, hospitalized patients with metastatic disease should be counseled before discharge, for example through outpatient transition [24], to reduce hospital readmission. Alternatively, down-staging efforts through an early stage at diagnosis, as secondary public health prevention, will indirectly reduce the rate of hospital readmission [2,9].
Anzeige
Similar to some but not all prior research, we found no association between readmission and comorbidities, LOS, or surgical approach. In a population-based study that assessed readmission rates in the VA population, the authors found no significant association between the aforementioned factors on the rate of readmission [25]. On the contrary, some other studies found a positive association with comorbidities, LOS, and open surgery. Notably, our population has longer index hospitalization compared to other populations [4,5,13,26]. It is possible that lack of association is due to the small observed number in the readmitted patients particularly those with > one comorbidity score.
The results of the present study should be interpreted within the scope of the following limitations. First, the reported results should be generalized to the MNG-HA population or a similar population. Second, SES is a factor that was affecting readmission in some previous studies which were not accounted for in the current study. Nonetheless, given that the MNG-HA population has equitable access to care and that all members are employed by the system, the SES effect is modest. Third, among patients with metastatic disease, we were not able to distinguish between primary tumor resection from metastatic resection. Fourth, given the positive volume-outcome relationship in CRC patients, adjusting for such factors could have improved the finding of the present study. Lastly, some of our admitted patients (n = 128) were missing discharge date and were excluded from analysis. The characteristics of these patients, nonetheless, were similar to our study population (Additional file 1: Appendix 2).
The knowledge of the rate and factors for hospital readmission in CRC patients has a significant impact on patients and the healthcare system. Given the identified factors, implementing strategies that may reduce readmission rates is needed. For instance, the adoption of minimally invasive surgery (e.g. laparoscopic procedure) could potentially contribute to lower hospitalization after major surgeries such as CRC. Additionally, post-discharge strategies include shorter outpatient follow-up time, nursing or home health care visits, and making a nursing/ educator home phone call. Many other modalities may be studied and implemented.
Conclusion
CRC readmission is common, especially in patients with metastatic disease. Strategies to reduce readmission include planned transition to outpatient care, especially among patients with a high risk of readmission.
Anzeige
Acknowledgements
The authors acknowledge the Research Data Management and Oncology Department at the Ministry of National Guard-Health Affairs (MNG-HA) for providing the data.
Declarations
Ethics approval and consent to participate
All methods were carried out in accordance with the Declaration of Helsinki. The study was reviewed and approved by King Abdullah International Medical Research Center (NRC21R/432/10), including the waiver of the informed consent.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Anzeige
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.
Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.
Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.
Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.